Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma drops lawsuit, ends its bid to buy cardiovascular-focused U.S. biotech, and hunts for other possibilities.
You may also be interested in...
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards
Astellas Wins OSI But Victory Comes At A Price
After months of drama, Astellas ups its bid to $4 billion cash to seal its hostile-turned-friendly bid for Tarceva maker OSI.